Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Enliven Therapeutics Inc’s stock clocked out at $21.73, up 8.11% from its previous closing price of $20.1. In other words, the price has increased by $8.11 from its previous closing price. On the day, 0.51 million shares were traded. ELVN stock price reached its highest trading level at $21.75 during the session, while it also had its lowest trading level at $20.19.
Ratios:
To gain a deeper understanding of ELVN’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 32.58 and its Current Ratio is at 32.58. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of. The stock’s future direction. In the most recent recommendation for this company, Goldman on June 16, 2025, initiated with a Buy rating and assigned the stock a target price of $37.
On December 13, 2024, BTIG Research started tracking the stock assigning a Buy rating and target price of $42.
On September 09, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $37.H.C. Wainwright initiated its Buy rating on September 09, 2024, with a $37 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 07 ’25 when Patel Anish sold 6,667 shares for $20.10 per share. The transaction valued at 133,993 led to the insider holds 276,641 shares of the business.
Hohl Benjamin sold 3,250 shares of ELVN for $66,291 on Sep 29 ’25. The CHIEF FINANCIAL OFFICER now owns 23,000 shares after completing the transaction at $20.40 per share. On Sep 26 ’25, another insider, Lyssikatos Joseph P, who serves as the CHIEF SCIENTIFIC OFFICER of the company, sold 4,000 shares for $20.25 each. As a result, the insider received 81,005 and left with 927,688 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ELVN now has a Market Capitalization of 1287188480 and an Enterprise Value of 797265408.
Stock Price History:
The Beta on a monthly basis for ELVN is 0.78, which has changed by -0.28265524 over the last 52 weeks, in comparison to a change of 0.14201736 over the same period for the S&P500. Over the past 52 weeks, ELVN has reached a high of $30.03, while it has fallen to a 52-week low of $13.30. The 50-Day Moving Average of the stock is 9.65%, while the 200-Day Moving Average is calculated to be 7.39%.
Shares Statistics:
It appears that ELVN traded 468.68K shares on average per day over the past three months and 409510 shares per day over the past ten days. A total of 59.23M shares are outstanding, with a floating share count of 41.88M. Insiders hold about 29.30% of the company’s shares, while institutions hold 76.05% stake in the company. Shares short for ELVN as of 1759190400 were 5699585 with a Short Ratio of 12.16, compared to 1756425600 on 4891510. Therefore, it implies a Short% of Shares Outstanding of 5699585 and a Short% of Float of 13.700000000000001.
Earnings Estimates
Current recommendations for the stock of the company come from 2.0 analysts. The consensus estimate for the next quarter is -$0.44, with high estimates of -$0.39 and low estimates of -$0.5.
Analysts are recommending an EPS of between -$1.59 and -$1.59 for the fiscal current year, implying an average EPS of -$1.59. EPS for the following year is -$1.64, with 1.0 analysts recommending between -$1.64 and -$1.64.
